Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Antiviral activity and CS… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Kontaktformulär








 


OBS! Vill du ha svar, ange e-post eller telefonnummer!




Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression

Artikel i vetenskaplig tidskrift
Författare M. S. Di Yacovo
J. Molto
E. Ferrer
A. Curran
L. Else
Magnus Gisslén
B. Clotet
J. M. Tiraboschi
J. Niubo
A. Vila
Henrik Zetterberg
D. Back
D. Podzamczer
Publicerad i Journal of Antimicrobial Chemotherapy
Volym 70
Nummer/häfte 5
Sidor 1513-1516
ISSN 0305-7453
Publiceringsår 2015
Publicerad vid Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi
Institutionen för biomedicin, avdelningen för infektionssjukdomar
Sidor 1513-1516
Språk en
Länkar dx.doi.org/10.1093/jac/dku558
Ämnesord antiretroviral therapy, HIV/AIDS, CSF, ART, CENTRAL-NERVOUS-SYSTEM, CEREBROSPINAL-FLUID, ANTIRETROVIRAL THERAPY, INFECTED PATIENTS, DARUNAVIR, PENETRATION, IMPACT, CNS, Infectious Diseases, Microbiology, Pharmacology & Pharmacy
Ämneskategorier Hematologi

Sammanfattning

Objectives: The objective of this study was to assess whether a lower dose than the currently used one of darunavir/ritonavir might achieve good CSF concentrations and contribute to inhibition of CNS viral replication. Patients and methods: This was a substudy of a randomized, open, multicentre study (eudraCT 2011-006272-39), comparing the efficacy and safety of 800/100 mg of darunavir/ritonavir (darunavir 800) versus 600/100 mg of darunavir/ritonavir (darunavir 600) once daily plus tenofovir/emtricitabine or abacavir/lamivudine in 100 virologically suppressed patients. Paired blood and CSF samples were obtained. Total plasma darunavir concentrations were determined by HPLC, and CSF concentrations by liquid chromatography-tandem MS. Viral load (VL) was determined in plasma and CSF (limit of detection = 40 copies/mL) by PCR. Results: Sixteen patients were enrolled. The median (range) of darunavir CSF concentrations in darunavir 600 (n = 8) and darunavir 800 (n = 8) patients was 17.08 (5.79-30.19) and 13.23 (3.47-32.98) ng/mL, respectively (P = 0.916). The median (range) darunavir CSF: plasma ratio was 0.010 (0.005-0.022) in darunavir 600 patients and 0.008 (0.004-0.017) in the darunavir 800 arm (P = 0.370). All 16 patients had a VL <40 copies/mL in plasma and 14 had a VL <40 copies/mL in CSF. Of the two patients with detectable CSF VL (280 copies/mL and 159 copies/mL), one was receiving darunavir 600 and the other darunavir 800 plus tenofovir/emtricitabine. Of note, these patients had the lowest CSF darunavir concentrations in their respective groups: 5.79 ng/mL (802 ng/mL in plasma) and 3.47 ng/mL (958 ng/mL in plasma). Conclusions: Darunavir CSF and plasma concentrations were comparable between the two arms. However, one patient from each group (with the lowest CSF darunavir concentrations in their respective groups) had detectable CSF VL despite undetectable plasma VL.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?